Tags : Teriflunomide

Sanofi’s Aubagio (teriflunomide) Receives EC’s Approval as First Oral MS

Tuba Khan June 21, 2021

Shots: The EC approval is based on a P-III TERIKIDS study evaluating Aubagioin vs PBO in 166 pediatric patients aged 10-17yrs. with RRMS across 22 countries globally, where a screening […]readmore

Clinical Trials Pharma

Sanofi to Present New Data of its Neurology Portfolio at

Tuba Khan September 9, 2020

Shots: Sanofi Genzyme reports the new data from the company’s neurology portfolio, to be presented at MSVirtual2020. The company will highlight new data on tolebrutinib (SAR442168), supporting its potential in […]readmore

Tags : Teriflunomide

Sanofi’s Aubagio (teriflunomide) Receives EC’s Approval as First Oral MS

Sanofi to Present New Data of its Neurology Portfolio at

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Teriflunomide

Sanofi’s Aubagio (teriflunomide) Receives EC’s Approval as First Oral MS

Sanofi to Present New Data of its Neurology Portfolio at

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company